The doctor recommended getting updated flu vaccines annually to lower the risk of contracting the virus and be protected from ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Report on how AI is redefining market landscape - The global effervescent tablet market size is estimated to grow by USD 4.80 billion from 2024-2028, according to Technavio. The market is estimated to ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

Find insight on GSK, Novo Nordisk, tariff escalation and more in the latest Market Talks covering Health Care.

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

GSK said at an R&D update in the summer that it expects to have two mRNA candidates in clinical trials within 12 months and six within the next four years, including seasonal flu shots.

The new agreement comes at a time when GSK and CureVac have been at risk of falling behind in mRNA vaccines for respiratory diseases, with combined flu/COVID-19 candidates from Moderna and Pfizer ...